2016 policy Priorities
MOBIO Supports passage of legislation that will define a clear pathway for the substitution of biologic drug products within our state's pharmacy practices act. Biosimilars are now in the market, and the FDA will soon commence approving "interchangeable" biological products that may be substituted without prior prescriber consent. These bills will increase access to lower costs drugs for patients, potentially save the state millions of dollars based on the state's own fiscal note, and establish meaningful consistency and access across the states which will longterm encourage biomanufacturing.
MOBIO Supports meaningful, recurring funding to the Missouri Technology Corporation and will pursue appropriation support for MTC's proven programs. MTC has proven itself adept at developing programs that encourage and attract private investment into emerging high-growth companies, many of which are focused in the biosciences. MTC investments have strengthened the state's economy, therefore MTC appropriations should continue to increase to match the market demand by innovative companies interested in growing here in Missouri.
MOBIO Supports investing in innovation, entrepreneurship and capital formation policies which enhance the state’s role in creating an environment that encourages the development of biotech and technology companies in Missouri.
MOBIO Opposes State by State mandates on food labeling for seed varieties derived from genetic engineering.
MOBIO Supports passage of a prescription drug monitoring program to prevent abuse by those who seek multiple prescriptions of highly addictive painkillers and controlled substances. Missouri is the last state in the nation without a PDMP.
MOBIO Supports passage of step therapy legislation that seeks to unify step therapy protocols with clinical practice guidelines.
Recurring Issues for the Life Sciences
MOBIO's leadership continues to speak with one voice and together we have championed the life sciences and high technology for over a decade. MOBIO remains committed to:
• Keep the state science friendly, working to defeat any scare tactic efforts that curtail unfettered research including the promising forms of stem cell research. Work to prevent research regulations that will hamper the delivery of needed health treatments and vaccines to patient populations.
• Work to find revenues for research capacity
• Work for policies and monies for commercialization and early state capital to our most promising bioscience companies
• Support long-term funding of MTC programs, including innovation centers
• Seek a business friendly environment to grow and protect our Missouri high-tech companies to succeed in the global environment
• Support higher education, STEM and workforce development initiatives that benefit the biosciences and address our state's science talent shortage..
MEMBERS ONLY - Follow the path of specific 2016 legislation tracked by the Missouri Biotechnology Association